

RESEARCH

Open Access



A reduction in CD90 (THY-1) expression results in increased differentiation of mesenchymal stromal cells

Daniela A. Moraes^{1,6}, Tatiana T. Sibov³, Lorena F. Pavon³, Paula Q. Alvim¹, Raphael S. Bonadio¹, Jaqueline R. Da Silva¹, Aline Pic-Taylor¹, Orlando A. Toledo², Luciana C. Marti⁴, Ricardo B. Azevedo¹ and Daniela M. Oliveira^{1,5*}

Abstract

Background: Mesenchymal stromal cells (MSCs) are multipotent progenitor cells used in several cell therapies. MSCs are characterized by the expression of CD73, CD90, and CD105 cell markers, and the absence of CD34, CD45, CD11a, CD19, and HLA-DR cell markers. CD90 is a glycoprotein present in the MSC membranes and also in adult cells and cancer stem cells. The role of CD90 in MSCs remains unknown. Here, we sought to analyse the role that CD90 plays in the characteristic properties of in vitro expanded human MSCs.

Methods: We investigated the function of CD90 with regard to morphology, proliferation rate, suppression of T-cell proliferation, and osteogenic/adipogenic differentiation of MSCs by reducing the expression of this marker using CD90-target small hairpin RNA lentiviral vectors.

Results: The present study shows that a reduction in CD90 expression enhances the osteogenic and adipogenic differentiation of MSCs in vitro and, unexpectedly, causes a decrease in CD44 and CD166 expression.

Conclusion: Our study suggests that CD90 controls the differentiation of MSCs by acting as an obstacle in the pathway of differentiation commitment. This may be overcome in the presence of the correct differentiation stimuli, supporting the idea that CD90 level manipulation may lead to more efficient differentiation rates in vitro.

Keywords: Mesenchymal stem cells, Mesenchymal stromal cells, CD90, Thy-1, Fibroblast, Differentiation

Background

Mesenchymal stromal cells (MSCs) are multipotent progenitor cells identified by their plastic-adherence when maintained under standard culture conditions, self-renewability, and differentiation into several mesodermal lineages [1–3]. MSCs are classically able to differentiate into osteoblasts, adipocytes, and chondroblasts in vitro [4]. Since their initial description as colony-forming cell units present in the bone marrow [5], MSCs have been isolated from many tissue sources such as placenta [6], dental pulp [7], tendons [8], scalp tissue [9], adipose tissue [10], umbilical cord blood [11], umbilical cord perivascular

cells [12], umbilical cord Wharton's jelly [13], synovial membrane [2], amniotic fluid [14], and breast milk [15]. Due to their relatively easy isolation, multi-differentiation potential, low antigenicity, and good proliferation/expansion in cell culture, MSCs are considered ideal candidates for cell-based regenerative therapies [16]. Based on the minimal criteria established by the International Society for Cellular Therapy (ISCT), human MSCs are identified by a combination of high CD105, CD73, and CD90 expression, and very low/no CD34, CD45, CD11a, CD19, and HLA-DR expression [4, 17]. Currently, there is no unique cell marker capable of solely isolating and defining MSCs. The observation that only a subpopulation of plastic-adherence isolated MSCs show multipotency [18] has led to a search for an ideal and definitive single MSC marker that would not only be specific to MSC, but would allow direct correlation with stemness [19].

* Correspondence: dmoliveira@unb.br

¹Departamento de Genética e Morfologia, Universidade de Brasília, Brasília, DF, Brazil

⁵IB-Departamento de Genética e Morfologia, Universidade de Brasília - UNB, Campus Universitário Darcy Ribeiro, Asa Norte, Brasília CEP 70910-970, Brazil
Full list of author information is available at the end of the article

Although CD90 and STRO-1 are broadly used to identify MSCs, neither of them is specific to MSCs [20–22]. STRO-1 is only expressed in a low percentage of MSCs. Some authors also discuss the absence of this marker in MSCs from all tissue sources [12, 19, 23], and it remains unclear, in the current literature, whether STRO-1 expression correlates to MSC stemness. On the other hand, CD90 is highly expressed in all MSCs, irrespective of the source, and it is a good marker for CFU-F enrichment [24]. High CD90 expression has also been related to the undifferentiated status of MSCs, since a decrease in CD90 level can be correlated with the temporal lineage commitment in vitro [25].

CD90, or Thy-1, is a 25–37 KDa glycosylphosphatidylinositol (GPI)-anchored glycoprotein [26]. CD90 was first detected in mice T cells [27] and later found to be expressed in thymocytes, T cells, neurons, hematopoietic stem cells, cancer stem cells, endothelial cells, and fibroblasts [28]. Although it has been shown that CD90 is conserved among different species, its function seems to vary according to cell type [29]. CD90 has been reported to participate in T-cell activation [30], neuritis outgrowth modulation [31], vesicular release of neurotransmitter at the synapse [32], astrocyte adhesion [33], apoptosis in carcinoma cells [34], tumour suppression [35–37], wound healing [38], fibrosis [39, 40], and fibrogenesis [41]. Furthermore, it regulates fibroblast focal adhesion, cytoskeleton organization, and cell migration [42]. In mouse models, activation of CD90 expression can be observed in inflammation, wound healing, and tumour development [43]. Recent studies suggest that CD90 has a role in oncogenesis, and it has also been proposed as a marker for cancer stem cells (CSCs) in various malignancies [44–51].

Despite an increasing number of studies suggesting CD90 participation in MSC self-renewal and differentiation [52], its function in MSC biology remains unknown. The unveiling of the function of CD90 in MSCs may further facilitate the in vitro manipulation of MSCs and consequently MSC-based therapies for regenerative medicine. In this study, we investigated the function of CD90 in MSC biology. To achieve this objective, we analysed the effect of CD90 knockdown on proliferation, morphology, and differentiation of human MSCs.

Methods

Subjects and cell culture

The cells were obtained with the approval of the Ethics Committee of the Faculty of Health Sciences at the University of Brasilia (Brazil) and University of São Paulo (Brazil). MSCs were isolated from healthy human tissues and cultured as previously reported. In the present study, we obtained MSCs from three different tissue sources: dental pulp [7] (three donors), adipose tissue [10] (two donors), and amniotic fluid [14] (two donors).

After isolation, cells were cryopreserved and stored in liquid nitrogen. For the assays we used cells that were stored for no longer than 1 year. Briefly, cells were thawed and expanded in a regular medium of Dulbecco's modified Eagle's medium (DMEM-LG; Sigma Chemical), supplemented with 10 % fetal bovine serum (FBS; Gibco), 100 units/ml penicillin, 100 mg/ml streptomycin (Gibco), and 10 μ l/ml L-glutamine (Gibco) at 37 °C, 5 % CO₂ [1]. The medium was changed every 48 h.

Lentiviral transduction for CD90 depletion

For lentiviral transduction, MSC isolates (a total of seven samples at cell passage 2) were cultured in a 75-cm² flask in medium containing 10 % FBS (Gibco), 100 units/ml penicillin, 100 mg/ml streptomycin (Gibco), 10 μ l/ml L-glutamin (Gibco) at 37 °C, 5 % CO₂. When cells reached a confluence of 60 %, transduction was performed in the presence of 8 μ g/ml Polybrene (Sigma-Aldrich) according to the manufacturer's instructions (Santa Cruz Biotechnology). CD90 small hairpin (sh)RNA-expressing lentivirus (shRNA CD90) or non-targeting shRNA-expressing scramble sequences of RNA (shRNA control) were then added to the cells at a multiplicity of infection (MOI) of 10. The medium was changed after 24 h. Three days after transduction, stable clones of MSCs expressing CD90-shRNA (shRNA CD90 MSC) and control shRNA (shRNA control MSC) were selected using 5 μ g/ml Puromycin (Sigma-Aldrich) for 10 days. The medium was changed every 48 h.

Real-time quantitative PCR

Total RNA was extracted from MSCs using Illustra RNAspin Mini (GE Healthcare), according to the manufacturer's guidelines. cDNA was prepared with High-Capacity cDNA Reverse Transcription (Applied Biosystems) and used as templates for polymerase chain reaction (PCR). The Kit Power Up SYBR Green Master Mix (Applied Biosystems) was used to quantify CD90 gene expression by quantitative real-time (qRT)-PCR under conditions recommended by the manufacturer and using the following primers: CACCCTCTCCGCACACCT (forward) and CCCAC-CATCCCACTACC (reverse). For normalization of the data, the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA was used (forward primer: AGAAGGCTGGGGCTCATTTG; reverse primer: AGGGGCCATCCACAGTCTTC). qRT-PCR was performed with the StepOne Plus Real-Time PCR System. A standard curve was generated for each primer pair, and genes of interest were assigned a relative expression value interpolated from the standard curve using the threshold cycle. All expression values were normalized against GAPDH. All amplifications were done in triplicate.

Magnetic separation of the MSCs for negative selection of CD90

Cell purification was performed according to the manufacturer's instructions (MiltenyiBiotec). To isolate the CD90-negative MSC population, shRNA CD90 MSCs were incubated with anti-CD90-coupled magnetic beads (MiltenyiBiotec, Germany) for 15 min at 4 °C, rinsed, and placed in a column. The negative fraction (CD90-negative MSCs) was collected, and cell purity checked by flow cytometry (FACSVERSE-BD Biosciences, San Jose, CA, USA) and FlowJo analysis software (TreeStar, Ashland, OR, USA).

Flow-cytometric analysis

Commercially available monoclonal antibodies were used for MSC immunophenotyping following the manufacturer's instructions. Subcultures at passage 3 were used for the flow-cytometric analysis. MSCs were lifted using TrypLE (Invitrogen, Carlsbad, CA, USA) and centrifuged for 5 min at 1000 rpm. The supernatant was discarded by aspiration and the cells incubated for 30 min in a dark environment in a flow cytometry buffer (phosphate-buffered saline (PBS), 2 % FBS) containing monoclonal antibodies against cell surface molecules and their respective isotype controls. The following antibodies were used: CD14-FITC; CD29-PE; CD31-PE; CD34-PE; CD44-PE; CD73-PE; CD90-APC; CD90-FITC; CD106-FITC; CD166-PE and CD166-PerCP-Cy5.5; CD45-PerCP-Cy5.5; HLA-DR-PerCP-Cy5.5 (Biosciences); and CD105-PE (clone 8E11; Chemicon, Temecula, CA, USA). Mouse IgG1-FITC, IgG1-PE, IgG1 PerCP-Cy5.5, IgG1-APC (Biosciences), and IgG2A-FITC (AbDSerotec, UK) were used as isotype controls. Cells were analysed using a fluorescence-activated cell sorter (CyFlowSpace-Partec, Germany; FACSVERSE-BD or FACSARIA-BD, both from BD Biosciences) and the data analysed using FlowJo analysis software (TreeStar).

MSC morphology analysis

Transduced and non-transduced MSCs at passage 3 were placed, in triplicate, in 24-well culture plates (5×10^4 cells/well). After cell concentration reached a confluence of 70 %, media were removed and the cells were washed with PBS and fixed with a 4 % paraformaldehyde solution for 15 min at room temperature. Cells were then washed with PBS, stained with Kit Instant Prov (NewProv, Brazil) and rewashed with PBS. Cell morphology (shape and size) was then analysed under an Axiovert inverted microscope (Zeiss, Germany) and EVOS FL cell imaging system (Life Technologies, Eugene, OR, USA).

Growth assay

For the assessment of growth characteristics, MSCs (1×10^5 cells, at passage 3 after transduction, passage 5 after isolation) were seeded in 75-cm² culture flasks in MSC

culture medium. Every 48 h, three replicate flasks were trypsinised and viable cells counted with a haemocytometer. MSC viability was evaluated by Trypan blue exclusion assay.

Lymphocyte proliferation assay

Peripheral blood mononuclear cells were isolated from peripheral blood and separated using the standard method with Ficoll-Paque PLUS (Amersham Biosciences, Uppsala, Sweden). The mononuclear cells were washed twice with PBS buffer. Cells were then counted in an automated cell counter (2.0 Scepter, Millipore), re-suspended to a final concentration of 10^4 cells/ml and labelled with CFSE (Sigma-Aldrich). The CFSE was adjusted to a final concentration of 5 μ M and incubated for 10 min at 37 °C. The reaction was stopped by adding RPMI with 10 % FBS. In immediate succession, 2×10^4 lymphocytes were cultured with or without 5×10^4 MSCs previously adhered to the bottom of a 24-well plate in a total volume of 1 ml per well of RPMI with 10 % FBS medium. To evaluate the lymphocyte proliferation rate in the presence of MSCs, cell suspensions were activated with a phytohaemagglutinin (PHA; Sigma, USA) stimulus at a final concentration of 1 μ g/ml in cell culture and maintained at 37 °C with 5 % CO₂ for 5 days for subsequent assessment by flow cytometry (CyFlowSpace-Partec, Germany) and the FlowJo analysis software (TreeStar) [53]. Suspension cells were stained with CD8-PE antibody (Biosciences), and lymphocyte proliferation was measured according to CFSE staining on gated population.

In vitro differentiation assays

To evaluate the differentiation potential of MSCs, cells were subjected to in vitro osteogenic and adipogenic differentiation according to the established protocols [1]. Transduced and non-transduced MSCs at passage 4 (passage 2 after transduction) were seeded in 24-well plates at a density of 5×10^4 cells/well. When a confluence of 80 % was achieved, the regular medium was replaced with an induction medium, which was refreshed every 72 h for 21 days. Cells cultured in regular medium were used as controls.

Osteogenic differentiation

MSCs were placed in 24-well plates at a density of 5×10^4 cells/cm² the previous day and then treated with osteogenic supplements as previously described [1] for 21 days. The osteogenic medium contained 100 nM dexamethasone (Sigma-Aldrich), 10 mM 2- β -glycero-phosphate (Sigma-Aldrich), and 50 μ M of L-ascorbic acid-2-phosphate (Sigma-Aldrich). Osteogenic differentiation was evaluated by alkaline phosphatase (ALP) activity, calcium concentration determination, and colorimetric Alizarin red

staining. Mineralized matrix formation after osteogenic differentiation was detected as previously described [1]. Samples were fixed with 4 % paraformaldehyde for 15 min, rinsed in PBS, and dyed for 20 min with 40 mM Alizarin Red solution (Sigma-Aldrich) at pH 4.2 and room temperature. Cells were washed five times with distilled water, followed by an immediate 15-min rinse with PBS to reduce non-specific dyeing. The resulting samples were analysed and photographed under an Axiovert inverted microscope (Zeiss, Germany). To determine alizarin red concentration, the samples were exposed to 10 mM sodium phosphate containing 10 % cetylpyridinium chloride (Sigma-Aldrich) at pH of 7.0 for 15 min at room temperature. The Alizarin Red concentration was determined by measuring absorption at 562 nm using a spectrophotometer (SpectraMax M2, Molecular Devices, USA). Results were expressed as a percentage of the respective controls, which were normalized to 100 % [54]. Lysate alkaline phosphatase activity was measured spectrophotometrically using a Sigmafast p-nitrophenyl phosphate kit (Sigma-Aldrich). For ALP assays, cells were washed with PBS and lysed in 0.05 % Triton X-100 through three cycles of freezing and thawing. A lysate aliquot was incubated with p-nitrophenyl phosphate substrate (p-NF) at 37 °C for 30 min. The reactions were stopped by adding 5 µl 1 N NaOH and absorbance measured at 405 nm using a spectrophotometer (SpectraMax M2, Molecular Devices) [55]. A pattern curve of p-NF was established in order to determine the enzymatic activity. Samples were normalized and total protein quantification determined by the Lowry method [56].

The quantitative levels of calcium in cell samples were determined for both osteogenic differentiation-induced and non-induced cells. Supernatant calcium concentration was determined by colorimetry using the ortho-cresolphthalein complexone (o-CPC) method [57]. Cells were trypsinised, resuspended in PBS, and then reacted with a calcium reagent containing 0.69 mol/l ethanolamine buffer, 0.2 % sodium azide, 0.338 mmol/l o-cresolphthalein complexone, and 78 mmol/l 8-hydroxyquinoline-13. Cell reactions were read by a spectrophotometer (Advia2400, Siemens).

Adipogenic differentiation

For adipogenic induction, cells were seeded in 24-well plates at a density of 5×10^4 cells/cm². When the cells reached confluence, they were treated with an adipogenic induction medium containing 5 mg/ml insulin, 5 mmol indomethacin, 1 mmol dexamethasone, and 0.5 mmol/l isobutyl-1-methylxanthine (all from Sigma-Aldrich) in regular medium. Adipocyte formation was monitored by the appearance of lipid droplets under a microscope. After the induction period, cytochemical analysis of the differentiated and control cells was performed by conventional optical microscopy. The cells

were fixed in 4 % formaldehyde for 15 min, rinsed in PBS, and dyed for 30 min with 0.5 % Oil Red O (Sigma-Aldrich) in ethanol. Cells were subsequently washed five times with distilled water to remove any excess dye. Quantification of lipid accumulation was achieved by extracting Oil Red-O from stained cells with isopropanol and measuring the OD of the extract at 510 nm using a Spectramax M2 spectrophotometer (Molecular Devices) [58].

Statistical analysis

Statistical analysis was performed using the software GraphPad™ (San Diego, CA, USA). Quantitative data were expressed as mean ± standard deviations (SD) and statistical analyses of variance (ANOVA). Multiple comparisons were performed with Tukey's HSD test when appropriate. Findings with $p < 0.05$ were considered statistically significant.


Results

MSC isolates and purity

MSCs were obtained from dental pulp (DPSC; three donors), amniotic fluid (AF-MSC; two donors), and adipose tissue (ADSC; two donors). The success rate of isolating MSCs from all tissues was 100 %. Cells from all three sources (a total of seven isolates) contained a high number of adherent MSC-like cells which proliferated rapidly in number. Analysis of positive and negative characteristics for human MSC surface antigens by flow cytometry for cultured MSCs showed a high purity (≥ 97 %) of the cells (Additional file 1: Table S1).

Analysis of the CD90 downregulated expression effect in MSCs

To initiate our study, we reduced CD90 expression in MSCs (DPSC, AF-MSC, and ADSC) by transducing commercially available lentiviruses expressing three CD90 shRNAs. After transduction, the MSC lines stably expressing shRNA CD90 and shRNA control were established by antibiotic selection. To confirm CD90 reduction, unmodified/non-transduced MSCs, shRNA CD90 MSCs, and shRNA control MSCs were analysed by flow cytometry (Fig. 1a and b) and qRT-PCR (Fig. 1c). Non-transduced MSCs and shRNA control MSCs showed the same level of CD90 expression (mean 98 %), whereas shRNA CD90 MSCs presented reduced CD90 expression (mean 23.9 %) (Fig. 1b). Transduction and establishment of shRNAs (CD90 and control) expressing MSCs were performed using samples from all tissues, with similar levels of reduction in CD90 expression observed in all samples (Additional file 1: Table S1). qRT-PCR confirmed that shRNA CD90 used here effectively reduced transcript levels of CD90 (Fig. 1c).



Since CD90 expression was not completely ablated in *shRNA CD90 MSCs*, we submitted *shRNA CD90 MSC* samples to magnetic-activated cell sorting and collected the post-separation CD90-negative fraction (subsequently termed CD90-negative MSCs). CD90-negative MSCs were characterized by flow cytometry to verify purification success. Flow cytometry analysis confirmed that the CD90-negative MSCs samples expressed lower levels of CD90 than *shRNA CD90 MSCs* (Fig. 2).

Morphology and growth kinetics

In our cellular morphology analysis of the cells used in this study, we observed no differences in the shape and size of MSCs, *shRNA control MSCs*, *shRNA CD90 MSCs*, CD90-negative MSCs, and non-transduced MSCs (Fig. 3a). The *shRNA CD90 MSCs* and CD90-negative MSCs derived from all three sources displayed characteristic MSC/fibroblast-like morphology. We also observed that *shRNA CD90 MSCs* and CD90-negative MSCs maintained their capacity to form colonies for up to 10 passages, suggesting that CD90 is not involved in the maintenance of MSC cell morphology and colony-forming ability.


In order to assess the role of CD90 in MSC proliferation rate, cell growth curves for MSCs, *shRNA control MSCs*, *shRNA CD90 MSCs*, CD90-negative MSCs, and non-transduced MSCs at the same corresponding cell passage (cell passage 5) were conducted in parallel (Fig. 3b). Analysis of the area under the curve showed no significant difference in proliferation rates. The trypan blue exclusion assay also showed no difference in cell viability.

Lymphocyte proliferation analysis

We also investigated whether CD90 expression in MSCs would affect the inhibitory effect of MSCs on non-specific mitogen-stimulated lymphocytes in an in vitro assay. The assay showed that *shRNA CD90 MSCs* and CD90-negative MSCs suppressed peripheral blood mononuclear cell proliferation to the same extent as MSCs and *shRNA control MSCs* and non-transduced MSCs (Fig. 4a and b), indicating that a reduction in the expression of CD90 does not affect the characteristic immunosuppressive effect of MSCs on lymphocyte proliferation. Further analysis shows that ablation of CD90 on MSCs also does not affect the percentage of proliferated CD8⁺ T cells (Fig. 4c).

Flow cytometry immunophenotyping


We further analysed the cell expression of the MSC marker panel. As expected, and as for non-transduced MSCs, *shRNA control MSCs*, *shRNA CD90 MSCs*, and CD90-negative MSCs were negative for the expression of the following markers: CD14, CD31, CD34, CD45, CD106, and HLA-DR, but they were positive for CD29, CD73, and CD105 (Additional file 1: Table S1 and Additional file 2: Figure S1). Surprisingly, we found a reduction in the expression of the CD44 and CD166 markers in *shRNA CD90 MSCs*, suggesting that the CD90 reduction is linked to the decrease in CD166 and CD44 expression (Fig. 5a and b). These reductions were observed in MSCs from all three sources (Fig. 5a).




CD90 and MSC differentiation

The differentiation potentials of non-transduced MSCs, shRNA control MSCs, shRNA CD90 MSCs, and CD90-negative MSCs were analysed in parallel in multilineage (osteogenic and adipogenic) differentiation assays. MSCs

isolated from dental pulp, amniotic fluid, and adipose tissue were submitted to osteogenic differentiation assays. As expected, osteogenic induction (OS) resulted in the occurrence of a mineralized matrix deposition which was detected 21 days after the initiation of differentiation






induction. The mineralized matrix was assessed by: a) Alizarin Red S Staining (AR); b) determination of calcium concentration; and c) alkaline phosphatase activity. According to previous data reported by other groups [7, 59, 60], mineral deposition was higher in MSCs isolated from dental pulp than in those isolated from lipoaspirate tissue (Fig. 6). The AR staining pattern obtained differs according to the level of CD90 expression (Fig. 6). The shRNA CD90 MSCs showed significantly higher production of osteogenic matrices, with the visualization of a higher concentration of AR dye in the samples, in comparison to both non-transduced MSCs and shRNA control MSCs (Figs. 6 and 7a). Even higher mineralization was observed in CD90-negative MSC samples. The effect of reduced CD90 expression on the osteogenic differentiation of MSCs was also assessed by monitoring alkaline phosphatase activity, which demonstrated an enhanced production of this enzyme in cells with reduced CD90 expression (Fig. 7b). The calcium production by shRNA CD90 MSCs was also higher than in non-transduced MSCs (Fig. 7b). The calcium concentration could not be adequately measured in samples originating from lipoaspirate tissue due to the low calcium concentration in all samples.

The adipogenic differentiation capacity of the MSCs was also analysed using MSCs isolated from dental pulp, adipose tissue, and amniotic fluid (Fig. 8). All cell populations showed significant morphological changes compared to those that were not incubated in adipogenesis-inducing medium. The cells presented an oval shape, with lipid vacuoles in the cytoplasm,

and the presence of many lipid droplets as evidenced by Oil Red staining (Fig. 8a). We observed an increase in the number of adipocyte-like cells in shRNA CD90 MSCs compared to the shRNA control MSCs, with an even higher number of adipocyte-like cells in CD90-negative MSCs. Independent of CD90 expression, we found that MSCs from adipose tissue produced higher amounts of lipid droplets when compared to cells obtained from the amniotic fluid and dental pulp. The most prominent adipocyte formation, revealed by Oil Red staining, was observed in CD90-negative MSCs isolated from adipose tissue (Fig. 8b).

Discussion


The biology of MSCs has been broadly studied [1, 22, 61, 62] because of their therapeutic potential. Therefore, we decided to study the function of CD90, one main immunophenotypical marker of MSCs, in order to better understand its relationship with MSC morphology, proliferation, and differentiation. Here, we used MSCs isolated from three sources (dental pulp, adipose tissue, and amniotic fluid) to verify whether the effects caused by CD90 ablation would be source-specific. We used lentivirus-mediated CD90-shRNAi to stably reduce CD90 expression and further evaluate its function in MSCs. Here, we generated MSC lines transduced with lentivirus-carrying small hairpins (shRNA) targeting CD90. After the establishment of CD90-shRNA expressing MSCs (in shRNA CD90 MSCs), the reduction of CD90 expression was confirmed



in immunophenotypic analysis using flow cytometry (Fig. 1). We subsequently evaluated the immunophenotypic profiles of modified MSCs, in addition to CD90. As expected, we found that these cells expressed the positive MSC markers CD29, CD73, and CD105, and did not express the following cell markers: CD14, CD31, CD34, CD45, CD106, and HLA-DR (Additional file 2: Figure S1). Surprisingly, we found that a knockdown in CD90 expression in all CD90-shRNAi MSCs obtained here led to a reduction in the CD44 and CD166 expression (Fig. 5).

The role of CD166 in MSCs has not been determined to date. However, CD44 (hyaluronan receptor) [63] is expressed by a large number of cells and is involved in

cell adhesion, migration, and homing in MSCs [64–66]. Furthermore, CD44 has been recognized as a stem cell marker for several types of cancer and is strongly linked to metastatic spread. It has been shown that the reduction of CD44 in cancer stem cells caused them to differentiate into non-cancer stem cells [67]. The receptor CD166 (activated leukocyte cell adhesion molecule, ALCAM) is a member of the immunoglobulin superfamily of cell adhesion molecules [68, 69] and is present in undifferentiated MSCs and other cell types [70]. Like CD44, CD166 has been shown to participate in tumour invasion [71–73]. A recent study using liver cancer cell lines relates the close interaction between CD44 and



CD166. The authors showed that a knockdown of CD166 inhibits the expression of CD44 via the NF κ B pathway [74].


CD90 has also been identified as a candidate marker for adult stem cells. Few studies have shown a functional association between CD90 and CD44 or CD166 markers. Strikingly, the few data showing association come from cancer stem cell research: CD90, CD44, and CD166 are notably considered cancer stem cell markers [44, 70, 71, 75]. Our results showed that the knockdown of CD90 leads to a decrease in CD44 and CD166 expression, which could indicate a shift in the stemness state of MSCs towards a state more susceptible to differentiation.

CD90 has been linked to the spindle-shape of lung fibroblasts. Observing lung fibroblasts sorted on the basis of CD90 expression, Phipps and co-workers [76] affirmed that the lung CD90⁻ fibroblast subpopulation showed a more polygonal shape than the spindle-shaped CD90⁺ fibroblasts. In contrast to these observations, in our study, a reduction in CD90 expression in shRNA CD90 MSCs and CD90-negative MSCs did not present altered morphology

or proliferation rate when compared to control cells (Fig. 3). Here, we also demonstrated that a reduced expression of CD90 does not affect the immunosuppressive activity of MSCs on lymphocyte proliferation in vitro (Fig. 5), a very important therapeutic MSC property.

We carried out assays to investigate the differentiation of CD90-ablated MSCs into osteogenic and adipogenic lineages. In our differentiation assays, shRNA CD90 MSCs and CD90-negative MSCs showed a higher rate of adipogenic differentiation when compared to the controls (Fig. 8). In the same way, an enhanced osteogenic differentiation was observed in samples of shRNA CD90 MSCs and CD90-negative MSCs. Alizarin Red S staining showed that CD90-negative MSCs, the CD90 negative fraction of shRNA CD90 MSCs, accumulated more mineralized matrix than shRNA CD90 MSCs (Figs. 6 and 7). According to our results, the knockdown of CD90 expression in MSCs facilitates osteogenic and adipogenic differentiation.

Recently, Woeller and colleagues [77] showed that CD90 controls adipogenesis. They had previously



observed that CD90-null mice gain weight at a faster rate, and that ectopic overexpression of CD90 blocked adipogenesis [77]. They also stated that, although pre-adipocyte fibroblasts expressed CD90, fat adipocytes presented almost undetectable CD90 levels. In agreement with this study, we also observed that a loss of CD90 expression in MSCs increased the production of adipogenic matrix in vitro. Based on their study, Woeller and colleagues [77] suggest that CD90 could be a new therapeutic target for obesity. However, our results indicate that this differentiation facilitation related to decreased CD90 expression is not only for adipogenic differentiation, since we observed the same facilitation for osteogenic differentiation. Our data indicate that the knockdown of CD90 seems to lower the stemness guard of MSCs, thereby enabling further differentiation when in the presence of the specific stimuli.

The finding that the level of CD90 regulates both MSC adipogenesis and osteogenesis is very interesting, because it is well accepted that differentiation stimuli usually cause an “inverse relationship” between adipogenic and osteogenic differentiation [78], although the molecular pathways that can converge into adipogenesis and osteogenesis have not been completely elucidated. Here, we demonstrated that the production of mineralized matrix directly correlates with the level of CD90 ablation: higher in the samples of CD90-negative MSCs than shRNA CD90 MSCs. It is unclear how CD90 can affect adipogenesis. However, it has been demonstrated that CD90 also regulates RhoGTPase activity in fibroblasts. Exogenous expression on CD90-non-expressing

fibroblasts results in Rho GTPase activation [42]. CD90 participates in many signalling pathways, and it is becoming clear that, although CD90 has been recognized as a plain cell marker, it is also an important regulator of MSC signalling [79]. In order to accurately understand the effects of CD90 on all *cis*- and *trans*-signalling networks that it participates in, significant further studies are required. Improving our knowledge of these mechanisms may allow a better understanding of MSC stemness and differentiation.

An increasing number of studies have shown that MSCs from different sources display significantly diverse properties and characteristics that may impact on their future therapeutic applications. The capacity of differentiation may vary according to the cell source [7, 59, 60]. In agreement with previous reports [59, 80–82], we observed that cells from the dental pulp tissue and amniotic fluid produced a larger quantity of osteogenic matrix than cells from adipose tissue (Figs. 6 and 7). Despite the expected variance in the differentiation potential among MSCs from different tissues [83, 84], we confirm that a reduction in CD90 expression leads to a more efficient osteogenic differentiation, irrespective of the source.

CD90 is a GPI-anchored protein expressed in various cell types. In general, it appears to influence cell proliferation, differentiation, migration, and survival. The functions of CD90 are tissue- and cell-specific and, in the present work, we found that shRNA-induced knockdown in human MSCs increases the




Fig. 8 Reduction of CD90 expression stimulates the adipogenesis of mesenchymal stromal cells (MSCs). MSCs, short hairpin (sh)RNA control MSCs, shRNA CD90 MSCs, and CD90-negative MSCs were tested for their ability to differentiate into adipogenic lineages. **a** Representative photomicrograph images show oil red staining indicative of adipogenic differentiation. MSCs from dental pulp (DPSC), amniotic fluid (AF-MSCs), and lipoaspirate (ADSC) were cultured in the non-differentiation medium MSCs (control) and adipogenic differentiation medium (AD). The images shown are representative of two independent experiments. **b** Oil red dye retained in the lipid vacuoles was measured by determining the optical density (OD) at 510 nm. Data shown represent the mean \pm SD of one experiment performed in triplicate ($n = 7$). * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$

differentiation efficiency of these cells. Our group previously showed that CD90 expression could be used as an indicator to follow the differentiation commitment degree

of MSCs. Immediately after the induction of differentiation, a progressive decrease in CD90 mRNA level correlates with the degree of differentiation observed [25]. It is

important to reiterate that the ablation of CD90 expression did not result in a spontaneous differentiation. However, it facilitated MSC differentiation in the presence of inductors, indicating that CD90 may play an important role in maintaining the undifferentiated state of MSCs, perhaps by acting as an obstacle to be overcome during the early steps of cellular differentiation commitment.

Conclusions

Taken together, the current data indicate that the ablation of CD90 in MSCs represents a promising alternative strategy and an efficient approach to increase MSC differentiation efficiency *in vitro*; it may, therefore, be used in the future to improve MSC differentiation yields in cellular therapy. Further studies are needed to evaluate whether this approach facilitates all the *in vitro* differentiation protocols established for MSCs, and how the ablation of CD90 affects migration/homing and the therapeutic potential of those cells in *in vivo* MSC therapy models. Our results showed that the knockdown of CD90 leads to a decrease in CD44 and CD166 expression, which could indicate a shift in the stemness state of MSCs towards a state that is more susceptible to differentiation.

Additional files

Additional file 1: Table S1. Surface protein expression of transduced and non-transduced MSCs originated from dental pulp (DPSC) ($n = 3$), amniotic fluid (AF-MSCs) ($n = 2$), and lipoaspirate (ADSC) ($n = 2$) were analysed by flow cytometry. Data shown represent the mean MFI \pm SD obtained in cytometry analysis performed in duplicate. (TIF 177 kb)

Additional file 2: Figure S1. Representative flow cytometry data to characterise transduced and non-transduced MSC groups studied in this work. One representative immunophenotypic analysis of groups obtained from the same dental pulp tissue is shown. Unstained MSC (grey shaded histogram), MSC (grey line), shRNA control MSCs (black slim line), and shRNA CD90 MSCs (black thick lines) were harvested and labelled with Ab against CD90, CD44, CD166, CD73, CD29, CD14, CD45, CD31, CD34, CD106, and HLA-DR as indicated. FACS analysis demonstrated that MSCs and shRNA CD90 MSCs were negative for CD14, CD45, CD31, CD106, HLA-DR, and CD34, and were positive for CD105, CD73, and CD29. MSCs were positive for CD90, CD44, and CD166, whereas shRNA CD90 MSCs showed a reduction in CD90, CD44, and CD166 expression. (TIF 8631 kb)

Abbreviations

ALP, alkaline phosphatase; CD, cluster differentiation; CFSE, carboxyfluorescein succinimidyl ester; CFU-F, colony-forming unit—fibroblast; HLA-DR, human leukocyte antigen—antigen D related; MSC, mesenchymal stromal cell; PBS, phosphate-buffered saline; PHA, phytohaemagglutinin; shRNA, small hairpin RNA

Acknowledgements

This work was supported by CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico). We thank the Sabin Laboratory (Brasília-DF, Brasil) for their technical help with calcium concentration analysis. We also thank Felipe Saldanha-Araújo for technical help with lymphoproliferation assays and Rafael Castro for technical help with flow cytometry assays.

Funding

Conselho Nacional de Pesquisa (Brazil) funded this study. The funders had no role in study design, data collection and analysis, the decision to publish, or the preparation of the manuscript.

Availability of data and materials

The authors confirm that all data underlying the findings are fully available.

Authors' contributions

DAM, TTS, LFP, JRS, RBA, and DMO contributed to the study design. DAM, TTS, LFP, OAT, PQA, AP-T, LMC, RSB, and DMO contributed substantially to data collection, study execution, and data analysis and interpretation. DAM wrote the first draft of the manuscript; and PQA, RSB, OAT, TTS, LFP, LCM, AP-T, JRS, RBA, and DMO contributed to the preparation of the manuscript and editing. All authors read and approved the manuscript.

Competing interests

The authors declare that they have no competing interests.

Ethics approval and consent to participate

Human tissues were obtained under approval of the Ethical Committee of Health Sciences Faculty of the University of Brasília (Brazil) (Project number CAAE 0020.0.012.000-08).

Author details

¹Departamento de Genética e Morfologia, Universidade de Brasília, Brasília, DF, Brazil. ²Departamento de Ciências da Saúde, Universidade de Brasília, Brasília, DF, Brazil. ³Departamento de Neurologia e Neurocirurgia, Universidade Federal de São Paulo, São Paulo, SP, Brazil. ⁴Hospital Israelita Albert Einstein, Instituto de Ensino e Pesquisa - Centro de Pesquisa Experimental São Paulo, São Paulo, SP, Brazil. ⁵IB-Departamento de Genética e Morfologia, Universidade de Brasília - UNB, Campus Universitário Darcy Ribeiro, Asa Norte, Brasília CEP 70910-970, Brazil. ⁶Centro Universitario do Distrito Federal UDF, Brasília, DF, Brazil.

Received: 12 April 2016 Revised: 28 June 2016

Accepted: 4 July 2016 Published online: 28 July 2016

References

- Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. *Science*. 1999;284:143–7.
- De Bari C, Accio FD, Tylzanowski P, Luyten FP. Multipotent mesenchymal stem cells from adult human synovial membrane. *Arthritis Rheum*. 2001;44:1928–42.
- Kadivar M, Khatami S, Mortazavi Y, Taghikhani M, Shokrgozar MA. Multilineage differentiation activity by the human umbilical vein-derived mesenchymal stem cells. *Iran Biomed J*. 2006;10:175–84.
- Dominici M, Le Blanc K, Mueller I, Marini FC, Krause DS, Deans RJ, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy*. 2006;8:315–7. doi:10.1080/14653240600855905.
- Friedestein A, Deriglasosa U, Kulagina N, Panasuk A, Rudakowa S, Lurià E, et al. Precursors of fibroblasts in different populations of hematopoietic cells as detected by the *in vitro* colony assay method. *Exp Hematol*. 1974;2:1408–19.
- Igura K, Zhang X, Takahashi K, Mitsuru A, Yamaguchi S, Takahashi TA. Isolation and characterization of mesenchymal progenitor cells from chorionic villi of human placenta. *Cytotherapy*. 2004;6:543–53. doi:10.1080/14653240410005366.
- Gronthos S, Mankani M, Brahmi J, Robey PG, Shi S. Postnatal human dental pulp stem cells (DPSCs) *in vitro* and *in vivo*. *Proc Natl Acad Sci U S A*. 2000;97:13625–30. doi:10.1073/pnas.240309797.
- Bi Y, Ehrlichou D, Kilts TM, Inkson CA, Embree MC, Sonoyama W, et al. Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. *Nat Med*. 2007;13:1219–27. doi:10.1038/nm1630.
- Shih DT, Lee D, Chen S, Tsai R, Huang C. Isolation and characterization of neurogenic mesenchymal stem cells in human scalp tissue. *Stem Cells*. 2005;23:1012–20. doi:10.1634/stemcells.2004-0125.
- Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, et al. Human adipose tissue is a source of multipotent stem cells. *Mol Biol Cell*. 2002;13:4279–95. doi:10.1091/mbc.E02.

11. Erices A, Conget P, Minguell J. Mesenchymal progenitor cells in human umbilical cord blood. *Br J Haematol.* 2000;109:235–42.
12. Sarugaser R, Lickorish D, Baksh D, Hosseini MM, Davies JE. Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. *Stem Cells.* 2005;23:220–9. doi:10.1634/stemcells.2004-0166.
13. Wang H, Hung S, Peng S, Huang C, Wei H, Guo Y, et al. Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. *Stem Cells.* 2004;22:1330–7. doi:10.1634/stemcells.2004-0013.
14. Tsai M, Lee J, Chang Y, Hwang S. Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. *Hum Reprod.* 2004;19:1450–6. doi:10.1093/humrep/deh279.
15. Patki S, Kadam S, Chandra V, Bhonde R. Human breast milk is a rich source of multipotent mesenchymal stem cells. *Hum Cell.* 2010;23:35–40. doi:10.1111/j.1749-0774.2010.00083.x.
16. Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. *Exp Mol Med.* 2013;45:1–16. doi:10.1038/emmm.2013.94.
17. Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. *Cytotherapy.* 2005;7:393–5. doi:10.1080/14653240500319234.
18. Russel K, Phinney D, Lacey M, Barrilleaux B, MMeyertholen KE, O'Connor KC. In vitro high-capacity assay to quantify the clonal heterogeneity in trilineage potential of mesenchymal stem cells reveals a complex hierarchy of lineage commitment. *Stem Cells.* 2010;28:788–98. doi:10.1002/stem.312.
19. Lv F-J, Tuan R, Cheung K, Leung V. Concise review: The surface markers and identity of human mesenchymal stem cells. *Stem Cells.* 2014;32:1408–19.
20. Miura M, Gronthos S, Zhao M, Lu B, Fisher LW, Robey PG, et al. SHED: stem cells from human exfoliated deciduous teeth. *Proc Natl Acad Sci U S A.* 2003;100:5807–12. doi:10.1073/pnas.0937635100.
21. Huang G, Gronthos S, Shi S. Mesenchymal stem cells derived from dental tissues vs. those from other sources: their biology and role in regenerative medicine. *J Dent Res.* 2009;88:792–806. doi:10.1177/0022034509340867.
22. Kolf CM, Cho E, Tuan RS. Review: mesenchymal stromal cells biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation MSC markers. *Arthritis Res Ther.* 2007;9:1–10. doi:10.1186/ar2116.
23. Hiwase SD, Dyson PG, To LB, Lewis ID. Cotransplantation of placental mesenchymal stromal cells enhances single and double cord blood engraftment in nonobese diabetic/severe combined immune deficient mice. *Stem Cells.* 2009;27:2293–300. doi:10.1002/stem.157.
24. Delorme B, Ringe J, Gallay N, Le Vern Y, Kerboeuf D, Jorgensen C, et al. Specific plasma membrane protein phenotype of culture-amplified and native human bone marrow mesenchymal stem cells. *Hematopoiesis Stem Cells.* 2008;111:2631–5. doi:10.1182/blood-2007-07-099622.
25. Sibov TT, Severino P, Marti LC, Van LF, Oliveira DM, Tobo PR, et al. Mesenchymal stem cells from umbilical cord blood: parameters for isolation, characterization and adipogenic differentiation. *Cytotechnology.* 2012;64:511–21. doi:10.1007/s10616-012-9428-3.
26. Williams AF, Gagnon J. Neuronal cell Thy-1 glycoprotein: homology with immunoglobulin. *Science.* 1982;216:696–703.
27. Raff M. Surface antigenic markers for distinguishing T and B lymphocytes in mice. *Transplant Rev.* 1971;6:52–80.
28. Rege TA, Hagood JS. Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis. *FASEB J.* 2006;20:1045–54. doi:10.1096/fj.05-5460rev.
29. Bradley JE, Ramirez G, Hagood JS. Roles and regulation of Thy-1, a context-dependent modulator of cell phenotype. *Biofactors.* 2009;35:258–65. doi:10.1002/biof.41.
30. Barboni E, Gormley AM, Rivero FBP, Vidal M, Morris R. Activation of T lymphocytes by cross-linking of glycopospholipid-anchored Thy-1 mobilizes separate pools of intracellular second messengers to those induced by the antigen-receptor/CD3 complex. *Immunology.* 1991;72:457–63.
31. Morris R, Tiveron M, Xue G. The relation of the expression and function of the neuronal glycoprotein Thy-1 to axonal growth. *Biochem Soc Trans.* 1991;20:401–5.
32. Jeng CJ, McCarroll SA, Martin TFF, Floor E, Adams J, Krantz D, et al. Thy-1 is a component common to multiple populations of synaptic vesicles. *J Cell Biol.* 1998;140:685–98. doi:10.1083/jcb.140.3.685.
33. Leyton L, Schneider P, Labra CV, Ruegg C, Hetz CA, Quest AFG, et al. Thy-1 binds to integrin $\beta 3$ on astrocytes and triggers formation of focal contact sites. *Curr Biol.* 2001;11:1028–38.
34. Hueber AO, Bernard AM, Battari CL, Marguet D, Massol P, Foa C, et al. Thymocytes in Thy-1^{-/-} mice show augmented TCR signaling and impaired differentiation. *Curr Biol.* 1997;7:705–8. doi:10.1016/S0960-9822(06)00300-9.
35. Lung HL, Bangarusamy DK, Xie D, Kwok A, Cheung L, Cheng Y, et al. THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma. *Oncogene.* 2005;24:6525–32. doi:10.1038/sj.onc.1208812.
36. Lung HL, Cheung AKL, Cheng Y, Kwong FM, Lo PHY, Law EWL, et al. Functional characterization of THY1 as a tumor suppressor gene with antiinvasive activity in nasopharyngeal carcinoma. *Int J Cancer.* 2010;127:304–12. doi:10.1002/ijc.25047.
37. Abeysinghe HR, Pollock SJ, Guckert NL, Veyberman Y, Keng P, Halterman M, et al. The role of the THY1 gene in human ovarian cancer suppression based on transfection studies. *Cancer Genet Cytogenet.* 2004;149:1–10. doi:10.1016/S0165-4608(03)00234-6.
38. Saalbach A, Anderegg U, Bruns M, Schnabel E, Hermann K, Hausteil U. Novel fibroblast-specific monoclonal antibodies: properties and specificities. *Soc Invest Dermatol.* 1996;106:1314–9.
39. Fries K, Blieden T, Looney R, Sempowski G, Silvera M, Willis R, et al. Evidence of fibroblast heterogeneity and role of fibroblast subpopulations in fibrosis. *Clin Immunol Immunopathol.* 1994;72:283–92.
40. Zhou Y, Hagood JS, Murphy-ullrich JE. Thy-1 expression regulates the ability of rat lung fibroblasts to activate transforming growth factor- β in response to fibrogenic stimuli. *Am J Pathol.* 2004;165:659–69.
41. Hagood JS, Prabhakaran P, Kumbala P, Salazar L, Macewen MW, Barker TH, et al. Loss of fibroblast Thy-1 expression correlates with lung fibrogenesis. *Am J Pathol.* 2005;167:365–79.
42. Barker TH, Grenett HE, MacEwen MW, Tilden SG, Fuller GM, Settleman J, et al. Thy-1 regulates fibroblast focal adhesions, cytoskeletal organization and migration through modulation of p190 RhoGAP and Rho GTPase activity. *Exp Cell Res.* 2004;295:488–96. doi:10.1016/j.yexcr.2004.01.026.
43. Jósavay K, Winter Z, Katona RL, Pecze L, Marton A, Buhala A, et al. Besides neuro-imaging, the Thy1-YFP mouse could serve for visualizing experimental tumours, inflammation and wound-healing. *Sci Rep.* 2014;4:1–7. doi:10.1038/srep06776.
44. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, et al. Significance of CD90 + cancer stem cells in human liver cancer. *Cancer Cell.* 2008;13:153–66. doi:10.1016/j.ccr.2008.01.013.
45. Lu J-W, Chang J-G, Yeh K-T, Chen R-M, Tsai JJP, Hu R-M. Overexpression of Thy1/CD90 in human hepatocellular carcinoma is associated with HBV infection and poor prognosis. *Acta Histochem.* 2011;113:833–8. doi:10.1016/j.jacthis.2011.01.001.
46. Sukowati CHC, Anfuso B, Torre G, Francalanci P, Crocè LS, Tiribelli C. The expression of CD90/Thy-1 in hepatocellular carcinoma: an in vivo and in vitro study. *PLoS One.* 2013;8:1–11. doi:10.1371/journal.pone.0076830.
47. Pascal LE, Ai J, Vêncio RZN, Vêncio EF, Zhou Y, Page LS, et al. Differential inductive signaling of CD90+ prostate cancer-associated fibroblasts compared to normal tissue stromal mesenchyme cells. *Cancer Microenviron.* 2011;4:51–9. doi:10.1007/s12307-010-0061-4.
48. True LD, Zhang H, Ye M, Huang C-Y, Nelson PS, von Haller PD, et al. CD90/THY1 is overexpressed in prostate cancer-associated fibroblasts and could serve as a cancer biomarker. *Mod Pathol.* 2010;23:1346–56. doi:10.1038/modpathol.2010.122.
49. He J, Liu Y, Zhu T, Zhu J, DiMeco F, Vescovi AL, et al. CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays. *Mol Cell Proteomics.* 2012;11:M1111.010744–4. doi:10.1074/mcp.M111.010744.
50. Zhu J, Thakolwiboon S, Liu X, Zhang M, Lubman DM. Overexpression of CD90 (Thy-1) in pancreatic adenocarcinoma present in the tumor microenvironment. *PLoS One.* 2014;9:1–20. doi:10.1371/journal.pone.0115507.
51. Ishiura Y, Kotani N, Yamashita R, Yamamoto H, Kozutsumi Y, Honke K. Anomalous expression of Thy1 (CD90) in B-cell lymphoma cells and proliferation inhibition by anti-Thy1 antibody treatment. *Biochem Biophys Res Commun.* 2010;396:329–34. doi:10.1016/j.bbrc.2010.04.092.
52. Maleki M, Ghanbarvand F, Behvarz MR, Ejtameai M, Ghadirkhomi E. Comparison of mesenchymal stem cell markers in multiple human adult stem cells. *Int J Stem Cells.* 2014;7:118–26.
53. Saldanha-Araujo F, Ferreira FIS, Palma PV, Araujo AG, Queiroz RHC, Covas DT, et al. Mesenchymal stromal cells up-regulate CD39 and increase adenosine production to suppress activated T-lymphocytes. *Stem Cell Res.* 2011;7:66–74. doi:10.1016/j.scr.2011.04.001.

54. Gregory CA, Gunn WG, Peister A, Prockop DJ. An Alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction. *Anal Biochem.* 2004;329:77–84. doi:10.1016/j.ab.2004.02.002.
55. Conconi MT, Tommasini M, Muratori E, Parnigotto PP. Essential amino acids increase the growth and alkaline phosphatase activity in osteoblasts cultured in vitro. *Farmacol.* 2001;56:755–61.
56. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. *J Biol Chem.* 1951;193:265–75.
57. Gitelman J. An improved automated procedure of calcium in biological for the determination specimens. *Anal Biochem.* 1967;18:521–31.
58. Sekiya I, Larson BL, Smith JR, Pochampally R, Cui J-G, Prockop DJ. Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality. *Stem Cells.* 2002;20:530–41.
59. Davies OG, Cooper PR, Shelton RM, Smith A, Scheven BA. A comparison of the in vitro mineralisation and dentinogenic potential of mesenchymal stem cells derived from adipose tissue, bone marrow and dental pulp. *J Bone Miner Metab.* 2014;37:1–82.
60. Divya MS, Roshin GE, Divya TS, Rasheed VA, Santhoshkumar TR, Elizabeth KE, et al. Umbilical cord blood-derived mesenchymal stem cells consist of a unique population of progenitors co-expressing mesenchymal stem cell and neuronal markers capable of instantaneous neuronal differentiation. *Stem Cell Res Ther.* 2012;3:1–16. doi:10.1186/scrt148.
61. Krampera M, Pasini A, Rigo A, Scupoli MT, Tecchio C, Malpeli G, et al. HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation. *Blood.* 2005;106:59–66. doi:10.1182/blood-2004-09-3645.
62. Feng J, Mantesso A, De Bari C, Nishiyama A, Sharpe PT. Dual origin of mesenchymal stem cells contributing to organ growth and repair. *Proc Natl Acad Sci U S A.* 2011;108:6503–8. doi:10.1073/pnas.1015449108.
63. Lesley J, Hascall VC, Tammi M, Hyman R. Hyaluronan binding by cell surface CD44. *J Biol Chem.* 2000;35:26967–75.
64. Zhu H, Mitsuhashi N, Klein A, Barsky LW, Weinberg K, Barr ML, et al. The role of the hyaluronan receptor CD44 in mesenchymal stem cell migration in the extracellular matrix. *Stem Cells.* 2006;24:928–35. doi:10.1634/stemcells.2005-0186.
65. Puré E, Cuff CA. A crucial role for CD44 in inflammation. *Trends Mol Med.* 2001;7:213–21.
66. Sapaeth EL, Labaff AM, Toole BP, Klopp A, Andreeff M, Marini FC. Mesenchymal CD44 expression contributes to the acquisition of an activated fibroblast phenotype via TWIST activation in the tumor microenvironment. *Cancer Res.* 2013;73(17). doi:10.1158/0008-5472.
67. Pham PV, Phan NL, Nguyen NT, Truong NH, Duong TT, Le DV, et al. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy. *J Transl Med.* 2011;9:209. doi:10.1186/1479-5876-9-209.
68. Bowen MA, Patel DD, Li X, Modrell B, Malacko AR, Wang W, et al. Cloning, mapping and characterization of activated leukocyte-cell adhesion molecule (ALCAM) a CD6 ligand. *J Exp Med.* 1995;181:2213–20.
69. Swart GW, Lunter PC, van Kilsdonk JW, van Kempen LC. Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering and cell migration. *Cancer Metastasis.* 2005;24:223–36. doi:10.1007/s10555-005-1573-0.
70. Bruder SP, Jaiswal N, Haynesworth SE. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. *J Cell Biochem.* 1997;64:278–94.
71. Lugli A, Iezzi G, Hostettler I, Muraro MG, Mele V, Tornillo L, et al. Prognostic impact of the expression of putative cancer stem cell colorectal cancer. *Br J Cancer.* 2010;103:382–90. doi:10.1038/sj.bjc.6605762.
72. Piscuoglio S, Lehmann FS, Zlobec I, Tornillo L, Dietmaier W, Hartmann A, et al. Effect of EpCAM, CD44, CD133 and CD166 expression on patient survival in tumours of the ampulla of Vater. *J Clin Pathol.* 2011;1–6. doi:10.1136/jclinpath-2011-200043.
73. Fujiwara K, Ohuchida K, Sada M, Horioka K, Iii CDU, Shindo K, et al. CD166/ALCAM expression is characteristic of tumorigenicity and invasive and migratory activities of pancreatic cancer cells. *PLoS One.* 2014;9:1–11. doi:10.1371/journal.pone.0107247.
74. Ma L, Pan Q, Sun F, Yu Y, Wang J. Cluster of differentiation 166 (CD166) regulates cluster of differentiation (CD44) via NF- κ B in liver cancer cell line Bel-7402. *Biochem Biophys Res Commun.* 2014;451:334–8. doi:10.1016/j.bbrc.2014.07.128.
75. Donnenberg VS, Donnenberg AD, Zimmerlin L, Landreneau RJ, Bhargava R, Wetzel RA, et al. Localization of CD44 and CD90 positive cells to the invasive front of breast tumors. *Cytometry B Clin Cytom.* 2010;78B:287–301. doi:10.1002/cyto.b.20530.
76. Phipps RP, Penney DP, Keng P. Characterization of two major populations of lung fibroblasts: distinguishing morphology and discordant display of Thy-1 and class II MHC. *Am J Respir Cell Mol Biol.* 1989;1:65–74.
77. Woeller CF, O'Loughlin CW, Pollock SJ, Thatcher TH, Feldon SE, Phipps RP. Thy1 (CD90) controls adipogenesis by regulating activity of the Src family kinase. *Fyn FASEB.* 2015;29:920–31. doi:10.1096/fj.14-257121.
78. James AW. Review of signaling pathways governing MSC osteogenic and adipogenic differentiation. *Scientifica.* 2013;2013:1–17. doi:10.1155/2013/684736.
79. Barker TH, Hagood JS. Getting a grip on Thy-1 signaling. *Biochim Biophys Acta.* 2009;1793:921–3. doi:10.1016/j.bbamcr.2008.10.004.
80. Ito K, Yamada Y, Nakamura S, Ueda M. Osteogenic potential of effective bone engineering using dental pulp stem cells, bone marrow stem cells and periosteal cells for osseointegration of dental implants. *Int J Oral Maxillofac Implants.* 2011;26:947–54.
81. Yu J, Wang Y, Deng Z, Tang L, Li Y, Shi J, et al. Odontogenic capability: bone marrow stromal stem cells versus dental pulp stem cells. *Biol Cell.* 2007;99:465–74.
82. Alge DL, Zhou D, Adams LL, Wiss BK, Shadday MD, Woods EJ, et al. Donor-matched comparison of dental pulp stem cells and bone marrow-derived mesenchymal stem cells in a rat model. *J Tissue Eng Regen Med.* 2010;4:73–81.
83. Chen XD, Qian HY, Neff L, Satomura K, Horowitz MC. Thy-1 antigen expression by cells in the osteoblast lineage. *J Bone Miner Res.* 1999;14:362–75. doi:10.1359/jbmr.1999.14.3.362.
84. Wiesmann A, Böhning H-J, Mentrup C, Wiesmann H-P. Decreased CD90 expression in human mesenchymal stem cells by applying mechanical stimulation. *Head Face Med.* 2006;2:1–6. doi:10.1186/1746-160X-2-8.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

